The filing is an Amendment No. 1 on Form 10-K/A to the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, primarily to correct a typographical error in the Audit Report date from March 27, 2025, to March 27, 2026, and to include currently dated certifications from the CEO and CFO. Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ALXN1840 for Wilson disease and novel radiopharmaceuticals (MNPR-101-Zr, MNPR-101-Lu, MNPR-101-Ac) for oncology. The company reported an accumulated deficit of approximately $89.5 million as of December 31, 2025, and has not generated any revenue since inception. Net loss for the year ended December 31, 2025, was $(13,716,894), an improvement from $(15,586,419) in 2024. Research and development (R&D) expenses decreased to $9,904,225 in 2025 from $13,005,986 in 2024. General and administrative (G&A) expenses increased to $6,800,190 in 2025 from $3,155,735 in 2024. Cash and cash equivalents significantly increased to $61,833,552 as of December 31, 2025, from $45,816,289 in 2024. Investments also saw a substantial increase to $78,565,491 as of December 31, 2025, from $14,395,913 in 2024. Total assets grew to $140,717,709 as of December 31, 2025, from $60,291,071 in 2024. Total stockholders' equity increased to $137,827,553 as of December 31, 2025, from $55,036,771 in 2024. Net loss per share (basic and diluted) was $(1.85) in 2025, compared to $(4.11) in 2024. Weighted average shares outstanding (basic and diluted) increased to 7,411,121 in 2025 from 3,790,202 in 2024, reflecting capital raises. In September 2025, the company completed an underwritten public offering, raising approximately $126.9 million in net proceeds from common stock and pre-funded warrants. Concurrently, the company repurchased 550,229 shares of its common stock from Tactic Pharma LLC for $35 million. Management estimates that currently available cash will provide sufficient funds to meet obligations at least through December 31, 2027, and has no substantial doubt about its ability to continue as a going concern for that period.